IN8bio (INAB) Biotech Showcase 2025 summary

Key scientific insights and clinical progress

• Gamma delta T cells, comprising 1%-7% of white blood cells, act as a 'special operations force' in the immune system, coordinating and directly killing cancer cells with high tolerability and safety.

• Clinical trials show no cytokine release syndrome, neurotoxicity, or significant infections, with many patients treated on an outpatient basis.

• The DeltEx platform leverages gamma delta T cells for ongoing immune surveillance, aiming for durable remissions and the eradication of tumor cells.

• Gamma delta T cells are polyclonal, can distinguish between healthy and tumor cells, and are associated with improved survival outcomes.

• Higher levels of gamma delta T cells correlate with a fourfold increase in survival rates in cancer patients.

Pipeline and program updates

• Ongoing clinical trials include INB-100 (leukemia, especially AML), INB-300 (non-signaling CAR-T), INB-500 (iPSC-derived T cells), and INB-600 (T cell engager platform).

• INB-200 and INB-400 target solid tumors, with INB-200 focused on glioblastoma; phase II was suspended due to cost, but cash runway extends into early 2026.

• INB-100 trial in AML patients shows durable remissions, with all first 10 patients surviving beyond one year and multiple patients beyond three years.

• Expansion of INB-100 to 25 patients is underway, with additional centers being added and new data expected in the first half of the year.

• INB-200 glioblastoma data show improved progression-free survival, especially with multiple doses, and immune cell infiltration into tumors.

Forward-looking statements and milestones

• Data updates for INB-100 and INB-200 are expected in the first half of the year, including expansion cohorts and real-world data.

• Preclinical data for the novel gamma delta T cell engager (INB-600) will be presented in the spring.

• The company has sufficient capital to fund operations and milestones through early 2026.

• The team includes leading experts in cell therapy, oncology, and biomarkers, supporting ongoing innovation and clinical progress.

• There is potential for gamma delta T cell therapies to expand into autoimmune disease, reflecting broader industry trends.